| Trial ID: | L6339 |
| Source ID: | NCT03470454
|
| Associated Drug: |
Linagliptin Oral Tablet
|
| Title: |
Contrast Nephropathy in Type 2 Diabetes
|
| Acronym: |
VCG4
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Function Affection Upon Exposure to Radiocontrast|Diabetes|Microalbuminuria
|
| Interventions: |
DRUG: Linagliptin Oral Tablet
|
| Outcome Measures: |
Primary: affection of estimated glomerular filtration rate, A significant decrease in estimated glomerular filtration rate (eGFR), Two months | Secondary: change in serum uric acid, A significant rise in serum uric acid, Two months | Other: Affection of albumin creatinine ratio, A significant increase in albumin creatinine ratio in urine (ACR), Two months
|
| Sponsor/Collaborators: |
Sponsor: Fayoum University | Collaborators: Boehringer Ingelheim
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
40
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2018-07-01
|
| Completion Date: |
2018-11-30
|
| Results First Posted: |
|
| Last Update Posted: |
2020-09-16
|
| Locations: |
Faculty of medicine Fayoum univesity, Fayoum, Egypt|Fayoum University, Fayoum, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT03470454
|
